ANI Pharmaceuticals Launches Generic Cymbalta Capsules in US Market
ANI Pharmaceuticals, Inc. (ANIP) has introduced its generic version of Duloxetine Delayed-Release Capsules in 20 mg, 30 mg, and 60 mg dosage strengths. The medication is a generic equivalent of Cymbalta, expanding the company's generic drug portfolio.
The launch addresses a sizable market segment, as annual U.S. sales for Duloxetine Delayed-Release Capsules reached approximately $247 million for the twelve months ending August 2026. Increasing availability offers healthcare providers and patients another supplier option in a market characterized by a limited number of active manufacturers.
Going forward, investors will be monitoring the commercial trajectory of the generic drug and its contribution to the company's broader growth strategy across its rare disease, generics, and branded medicine divisions.
Key points
- ANI Pharmaceuticals, Inc. launched generic Duloxetine Delayed-Release Capsules in 20 mg, 30 mg, and 60 mg strengths.
- The product serves as a generic equivalent to the brand-name medication Cymbalta.
- Annual U.S. market sales for duloxetine capsules totaled about $247 million for the period ending August 2026.
- The launch introduces an additional supply source in a market with limited competing manufacturers.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What drug did ANI Pharmaceuticals recently launch?
ANI Pharmaceuticals launched generic Duloxetine Delayed-Release Capsules in 20 mg, 30 mg, and 60 mg dosages, which are generic versions of Cymbalta.
How large is the U.S. market for generic Cymbalta?
Annual U.S. sales for Duloxetine Delayed-Release Capsules reached approximately $247 million for the twelve months ending August 2026.
Why is this product launch significant for ANI Pharmaceuticals?
It adds a widely used therapy to the company's generics lineup and provides an additional supplier in a market with few active manufacturers.